Price
No data yet.
Social Signal Score
Analyst Ratings
4 analystsRevenue
$12.88MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Mary T. Szela
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 102
- Beta
- 0.51
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -6.41
Financials
Revenue
$12.88M+401.9%Net Income
$-8.85MEBITDA
$-7.29MFree Cash Flow
$-5.37MEPS (diluted)
$-0.15Shares Outstanding (diluted)
58.47M+91.3%Operating Expenses
$18.80MCash & Debt
$41.06MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $45.15M | $-39.23M | $-1.84 |
| 2024 | $29.43M | $-33.23M | $-1.25 |
| 2023 | $18.51M | $-59.36M | $-2.23 |
| 2022 | $12.40M | $-47.19M | $-1.59 |
| 2021 | $8.40M | $-28.84M | $-0.92 |
| 2020 | $0.00 | $-31.83M | $-0.02 |
Valuation
TLSIhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
160+1500.00%Social Signal Score
Mentions (7)
- Newsmarketbeat.com·12d ago·Positive
TriSalus Life Sciences Q3 Earnings Call Highlights TriSalus Life Sciences NASDAQ: TLSI reported third-quarter revenue growth of 11% but updated its full-year outlook as newly added sales territories took longer than expected to become productive.
View source ↗ - Newsseekingalpha.com·12d ago·Positive
TriSalus Life Sciences, Inc. (TLSI) Q3 2026 Earnings Call Transcript TriSalus Life Sciences, Inc. (TLSI) Q3 2026 Earnings Call Transcript
View source ↗ - Newsbusinesswire.com·12d ago·Neutral
TriSalus Life Sciences Reports Third Quarter 2026 Results DENVER--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announced financial results for the quarter ended September 30, 2026, and provided an operational update. “The third quarter marked an important period of growth …
View source ↗ - Newsbusinesswire.com·33d ago·Neutral
TriSalus Life Sciences to Host Third Quarter 2026 Financial Results Conference Call WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard-of-care therapies and an investigational immunotherapeutic to transform outcomes for patients with solid tumors, today announced that it will host a conference call and webcast on Tuesday, November 10, 2026, at 8:30 AM eastern time to discuss its…
View source ↗ - Newsbenzinga.com·60d ago·Negative
TriSalus Secures FDA Clearance For TriNav Advance as Stock Tests Key Support The U.S. Food and Drug Administration (FDA) on Wednesday granted 510(k) clearance for TriSalus Life Sciences Inc.'s (NASDAQ:TLSI) TriNav Advance, the newest addition to its Pressure-Enabled Drug Delivery (PEDD) portfolio.
View source ↗ - Newsbusinesswire.com·61d ago·Negative
…ing Comprehensive Pressure-Enabled Drug Delivery™ (PEDD™) Portfolio for Liver Embolization WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard-of-care therapies and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for TriNav® Advance, the newest add…
View source ↗ - Newsmarketbeat.com·96d ago·Neutral
TriSalus Highlights Tumor-Treatment Expansion, FDA Catalyst at Growth Conference TriSalus Life Sciences NASDAQ: TLSI outlined its commercial expansion, product pipeline and clinical-evidence strategy during Canaccord Genuity's Global Growth Conference, with management emphasizing the company's pressure-enabled delivery technology for solid-tumor treatments.
View source ↗
Earnings
Thu, Mar 4(in 3 months)
Consensus estimate $-0.13 per share
Typical surprise -42.1% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Nov 10$-0.15 vs $-0.13miss
- Thu, Aug 6$-0.16 vs $-0.15miss
- Tue, May 12$-0.33 vs $-0.16miss
- Thu, Mar 5$-0.21 vs $-0.13miss
- Thu, Nov 13$-0.96 vs $-0.17miss
- Tue, Aug 12$-0.27 vs $-0.22miss
Estimates and results for TLSI via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by TLSI officers and directors.
- Bought
- $3.7m
- Sold
- $141k
13 trades
19 trades
- Marshak Richardsold
- Wahlstrom Matsbought
- Cox Bryan F.sold
- Marshak Richardsold
- Stevens Jennifersold
- Marshak Richardsold
- Wahlstrom Matsbought
- Stansky Michael Pbought
68 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in TLSI.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
